Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study.

@article{Machytka2017ElipseTF,
  title={Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study.},
  author={Ev{\vz}en Machytka and Shantanu K. Gaur and Ram Chuttani and Martina Bojkov{\'a} and Tomas Kupka and Marek Bu{\vz}ga and Andreas Giannakou and Kandiliotis Ioannis and Elisabeth M. H. Mathus-Vliegen and Samuel L{\'e}vy and Ioannis Raftopoulos},
  journal={Endoscopy},
  year={2017},
  volume={49 2},
  pages={
          154-160
        }
}
Background and study aims Conventional gastric balloons for weight loss require endoscopy for placement and removal. The Elipse device is swallowed, resides in the stomach for 4 months, and is then expelled. The objectives of this study were to assess the safety of Elipse and to measure its effects on weight loss, metabolic parameters, and quality of life. Methods Each participant swallowed one Elipse device, which was filled with 550 mL of filling fluid through a thin delivery catheter that… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS